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Abstract
The TNF receptor superfamily member CD95 (Fas, APO-1, TNFRSF6) is known as the prototypic death receptor in
and outside the immune system. In fact, many mechanisms involved in apoptotic signaling cascades were solved
by addressing consequences and pathways initiated by CD95 ligation in activated T cells or other “CD95-sensitive”
cell populations. As an example, the binding of the inducible CD95 ligand (CD95L) to CD95 on activated T
lymphocytes results in apoptotic cell death. This activation-induced cell death was implicated in the control of
immune cell homeostasis and immune response termination. Over the past years, however, it became evident that
CD95 acts as a dual function receptor that also exerts anti-apoptotic effects depending on the cellular context.
Early observations of a potential non-apoptotic role of CD95 in the growth control of resting T cells were recently
reconsidered and revealed quite unexpected findings regarding the costimulatory capacity of CD95 for primary T
cell activation. It turned out that CD95 engagement modulates TCR/CD3-driven signal initiation in a dose-
dependent manner. High doses of immobilized CD95 agonists or cellular CD95L almost completely silence T cells
by blocking early TCR-induced signaling events. In contrast, under otherwise unchanged conditions, lower amounts
of the same agonists dramatically augment TCR/CD3-driven activation and proliferation. In the present overview,
we summarize these recent findings with a focus on the costimulatory capacity of CD95 in primary T cells and
discuss potential implications for the T cell compartment and the interplay between T cells and CD95L-expressing
cells including antigen-presenting cells.
Introduction
Members of the ‘tumour necrosis factor receptor’
(TNFR) superfamily and their ligands are crucial regula-
tors of cellular activation and death. According to their
structural composition and/or cellular function, the
TNFR family can be further divided into the three sub-
groups of ‘death domain’ (DD)-containing receptors,
‘TNFR-associated factor’ (TRAF) binding receptors and
decoy receptors. The eponymous ‘TNF receptor-1’
(TNFR-1, TNFRSF1), CD95 (Fas, APO-1, TNFRSF6)
and ‘TNF-related apoptosis inducing ligand’ (TRAIL)
receptors (DR4/TNFRSF10A, DR5/TNFRSF10B), contain
cytoplasmic death domains, which are essential for the
direct induction of cell death. In contrast, the TNFR
family members TNFR-2, CD27, 4-1BB (CD137), OX-40
(CD134), ‘herpesvirus entry mediator’ (HVEM), CD30
and ‘glucocorticoid-induced TNFR family related pro-
tein’ (GITR) belong to the subgroup of TRAF binding
receptors that lack a characteristic DD, but harbor 4-6
amino acids important for the recruitment of TRAF
proteins. These receptors have been mainly implicated
in non-apoptotic processes including cellular activation,
differentiation and survival [1], but they might also be
involved in other forms of cell death, e.g. programmed
necrosis as in the case of TNFR-2 [2].
Although the DD-containing receptors have been
mainly associated with the induction of apoptosis, these
receptors can also exert non-apoptotic functions in a
wide range of different cell populations. Thus, several
“death receptors” have been implicated in the signal
induction for activation, migration, proliferation or dif-
ferentiation. As an example, agonistic anti-CD95 antibo-
dies caused massive CD95-induced hepatitis in normal
mice but increased liver regeneration in mice subjected
to hepatectomy [3]. For TNFR-1, it was proposed that
receptor internalization and the formation of TNF
receptosomes transmit pro-apoptotic signals, whereas
plasma membrane-associated receptors trigger non-
apoptotic signaling to activate ‘nuclear factor ‘kappa-
light-chain-enhancer’ of activated B-cells’ (NF-B) [4].
Thus, the very same DD receptors can exert pro- or
anti-apoptotic effects in a context-specific fashion and
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tion or on signaling thresholds governed by other simul-
taneous cell-cell-interactions.
CD95 - the prototype of a death receptor
The 45 kDa type-I transmembrane protein CD95 is a
member of TNFR family and serves as the prototypic
death receptor for the immune system. CD95-dependent
apoptosis is triggered by CD95L (FasL, APO-1L,
TNFSF6) binding and clustering of surface CD95. Oligo-
merization initiates the recruitment of the ‘Fas (CD95)
associated protein with death domain’ (FADD) and pro-
caspase-8 to form the ‘death-inducing signaling com-
plex’ (DISC) [5,6]. In this multimolecular complex,
procaspase-8 undergoes autocatalytic cleavage resulting
in the generation of active caspase-8, which in turn reg-
ulates the extrinsic pathway leading to apoptotic cell
death [7,8].
CD95: a death receptor for lymphocyte homeostasis
The importance of the CD95/CD95L-system for lym-
phocyte homeostasis became apparent from the initial
observation that naturally occurring mice which devel-
oped massive lymphadenopathy and suffered from lym-
phoproliferative syndromes carried the causative
mutations in the genes encoding either for CD95 (lpr =
lymphoproliferation) or for CD95L (gld = generalized
lymphoproliferative disease). In both types of mice, the
impaired CD95/CD95L-interaction resulted in an accu-
mulation of unconventional T cells (Thy-1
+CD4
-CD8
-
TCRa/b
+B220
+) as well as in increased numbers of con-
ventional B cells and CD4
+ and CD8
+ T cells [9-11].
This clearly suggested that signaling through the death
receptor CD95 governs homeostasis of the lymphoid
system. Since the observed pathology was apparently
caused by a defective killing/dying capacity affecting
both immature and mature cell populations, the pheno-
type might however have better been summarized as
lymphoaccumulation rather than lymphoproliferation.
Although functional defect mutants of CD95 or CD95L
are rare in humans, the consequences of an impaired
removal of pre-activated potentially dangerous cells are
also characteristic for patients suffering from certain
types of autoimmune lymphoproliferative syndrome
(ALPS) [12,13].
In essence, lpr/gld- or ALPS-pathologies were asso-
ciated with an impaired ‘activation-induced cell death’
(AICD). Briefly, AICD describes an activation-driven
death that is associated with an induced increase in
CD95L expression (e.g. following multiple TCR stimula-
tions) which in turn results in suicidal or fratricidal
CD95-mediated apoptosis. There is no doubt that death
receptors play a prominent role in the development of
AICD sensitivity [14,15]. However, it was also reported
that death receptor independent signals via the TCR
contribute to apoptosis sensitivity. One mechanism
involves the cleavage of the ‘hematopoietic progenitor
kinase-1’ (HPK-1), which in turn binds to the ‘inhibitor
of B( I B) kinase’ (IKK) complex and thereby interferes
with pro-survival signaling by NF-B [16]. Notably, acti-
vated T cells which are not restimulated die by ‘acti-
vated cell autonomous death’ (ACAD), a process which
is also termed passive cell death or death by neglect and
can also be observed under conditions of cytokine with-
drawal [17].
Both ACAD and AICD have been implicated in thy-
mocyte selection and the termination of the immune
responses providing an effective means for the removal
of useless cells. If one of the control mechanisms is
missing, due to functional impairment of the trigger sys-
tem or the involved signaling molecules, immature or
mature cells might escape immune selection, and poten-
tially dangerous autoreactive cells accumulate in lym-
phoid organs and in the periphery. Therefore, mutations
in several genes encoding for apoptosis regulators (e.g.
ligands, receptors, adapter proteins or caspases) cause
immune dysfunction and severe autoimmunity as
observed in ALPS patients and respective animal
models.
Death receptors such as CD95 trigger the extrinsic
apoptosis pathway. They deliver pro-apoptotic signals at
t h ep l a s m am e m b r a n eb yf o r m a t i o no faD I S Ca n db y
subsequent direct activation of a proteolytic caspase sig-
naling cascade in so-called ‘type I’ cells or via an addi-
tional (intrinsic) mitochondrial amplification loop in
‘type II’ cells. As mentioned, the earlier studies on
AICD suggested a prominent role of CD95 in this con-
text [6,14]. However, more recent studies propose that
the pro-apoptotic BH3-only protein ‘Bcl-2-interacting
mediator of cell death’ (Bim), a member of the Bcl-2
protein family and thus a mediator of the mitochondrial
apoptosis route, is also involved in the deletion of per-
ipheral T cells [18-21]. Therefore, it has to be con-
cluded that CD95 and Bim play a synergistic or
cooperative role in the contraction phase of T cell
responses, and link the different branches of the intra-
cellular apoptosis machinery [22].
CD95 - a dual-function receptor
Apart from its primary pro-apoptotic role, follow-up
studies revealed that CD95 might rather act as a dual-
function signaling receptor with tissue-specific functions
and give rise to pro- and anti-apoptotic signals depend-
ing on the cellular microenvironment [8]. Thus, CD95
was found to affect proliferation, differentiation and
migration processes as well as cytokine production in
different hematopoietic and non-hematopoietic cell
types. Moreover, a very recent study discovered that
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toxic activity, whereas soluble CD95L (generated when
mCD95L is proteolytically cleaved by matrix metallopro-
teinases [23]) primarily promotes non-apoptotic activ-
ities [24] and even neutrophil chemotaxis [25].
As an apostil, non-apoptotic regulatory functions of
the CD95L have also been suggested. This phenomenon,
referred to as reverse or retrograde signaling, has been
documented for several TNF ligands and increases the
levels of complexity and plasticity during pro-and-anti-
apoptotic cell-cell communication. Here, CD95 operates
as the ligand for membrane-bound CD95L to induce
signal alterations in the CD95L-expressing cell. How-
ever, the available data on the role of CD95L reverse
signaling in T cells are still fragmentary. What is known
is that reverse signaling in different T cell subsets
requires a presumably simultaneous TCR/CD3-engage-
ment. In terms of outcome and signaling pathways, the
reported findings are, however, still somewhat confusing
since they span from promotion of proliferation to cell
cycle arrest [23,26-30].
As indicated, anti-apoptotic effects of CD95 seem to
depend on several parameters including the cell type
and cellular context, the mode of ligation, and the acti-
vation-associated signaling threshold. However, non-
apoptotic or even costimulatory consequences of CD95
engagement were only sporadically reported for instance
during liver regeneration, development and functional
recovery of the central nervous system or neurite out-
growth, and the proliferation of growth factor deprived
fibroblasts [31]. Only recently, it became evident that
CD95 ligation might be highly relevant for the modula-
tion of TCR/CD3 signaling in primary T cells.
CD95 as a non-apoptotic costimulatory molecule for T
cells
The textbooks tell that three signals are required for full
activation and differentiation of resting T cells. The first
signal emerges from an engagement of the TCR/CD3
complex, the second costimulatory signal is provided
through the ligation of “classical” costimulatory recep-
tors including CD28 or CD278 (ICOS) and the third sig-
nal for differentiation is provided by locally available
cytokines. However, in recent years, TRAF binding
receptors were identified as a second class of costimula-
tory receptors [1].
Based on experiments in gld-a n dlpr-mice, Alderson
and colleagues provided first evidence for a potential
role of CD95 in the activation of human T cells in
1993 when they reported a stronger proliferation and
cytokine production in the presence of a functional
CD95L/CD95-system [32]. It was subsequently
reported that CD95-mediated costimulation involved
activation of caspases in the absence of apoptosis
[33,34]. However, since T cell activation through the
TCR alone apparently also depended on caspase pro-
cessing, it was concluded that caspase activation plays
a more general role in proliferative processes and
under such costimulatory conditions might not neces-
sarily be associated with death receptor signaling
[34-36]. Along this line, caspase-8 mutations in
humans were found to be associated with severe T cell
associated immune dysfunction [37]. Whereas cleavage
of the classical caspase substrate ‘Poly(ADP-Ribose)
Polymerase’ (PARP) in this scenario has been initially
observed by Alam et al. [34], recent data from others
and our own experiments rather point to a non-apop-
totic caspase activation that spares cleavage of apopto-
sis-relevant substrates such as PARP [38]. More
precisely, we demonstrated an incomplete cleavage of
caspase-3 resulting in an accumulation of the p20 frag-
ment under costimulatory conditions. Concomitantly,
p17 and p19 fragments, which are characteristic for
caspase-3 activity in apoptotic cells, were not seen in
TCR/CD3-stimulated cells in the presence of CD95
agonists. We conclude that caspase activation is
required for proliferation, but that non- or pro-apopto-
tic caspase activation is qualitatively different
[35,38,39]. In view of our recent observation that the
‘X-linked-inhibitor-of-apoptosis-protein’ (XIAP) can
interact with caspase-3 and thereby block full caspase
activation [38], we suggest that in naïve T cells, CD95
initiates an incomplete cleavage of caspase-3, thereby
presumably hindering the cleavage of pro-apoptotic
substrates. Thus, caspase-3 activation in this scenario
might affect different substrates, which in turn are cru-
cial for supporting a proliferative response. However,
different caspase substrate repertoires associated with
proliferation and apoptosis, respectively, have to be
proven and characterized. So far, only limited numbers
of putative anti-apoptotic caspase substrates have been
described that include RasGAP [40] or HPK-1 [41-43].
In this context, a very recent study describe a systema-
tic computational screening method of caspase clea-
vage sites to provide more insight into the substrate
specificity of caspases and facilitate the discovery of
putative novel substrates [44].
One mechanism to balance caspase activity during
survival and cell death has been discussed by Kurokawa
and Kornbluth [45]. In their review, they summarize
how phosphorylation can alter activities of both caspases
and their potential targets (e.g. kinases and phospha-
tases), and how these classes of signaling molecules are
linked to control apoptosis and survival. As an example,
phosphorylation of nuclear caspase-2 at Ser122 by a
DNA-dependent protein kinase induces non-apoptotic
activation of the caspase and results in cell cycle arrest
at a G2/M DNA damage checkpoint to allow DNA
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enzymes with multiple functions beyond cell death
induction depending on posttranslational modifications.
Interestingly, in the context of non-apoptotic caspase
activation by CD95 costimulation, a contribution to
altered phosphorylation of caspases und their substrates
has not been investigated. Furthermore, it still has to be
clarified for non-apoptotic signaling, whether CD95
directly recruits or activates caspases via its adapter
molecule FADD or whether CD95 only supports the
TCR-mediated activation of caspases via a signaling
complex formed for example by ‘B-cell CLL/lymphoma
associated 10’ (Bcl-10), ‘CARD-containing MAGUK pro-
tein1’ (CARMA1) and ‘mucosa-associated lymphoid tis-
sue-1’ (MALT-1) [47].
An additional level of regulation of life and death
decisions in T cells is represented by the molecule ‘cel-
lular FLICE (caspase 8)-like inhibitory protein’ (cFLIP).
cFLIP can inhibit death receptor signaling and caspase-8
activation, possibly through competition with caspase-8
for the recruitment to FADD. However, it has also been
shown that cFLIP mediates activation of full-length cas-
pase-8 at the DISC, which in turn results in caspase-8-
induced cleavage of cFLIP. Apparently, this process
requires the cleavage of cFLIP to a p43-fragment [48].
More recently, it was argued that p22-cFLIP (but not
p43) can activate NF-B by directly interacting with the
IKK complex [49]. Cleaved cFLIP then allows a more
efficient recruitment of TRAF1/2, the ‘receptor-interact-
ing protein’ (RIP1) and the the ‘rapidly growing fibrosar-
coma or rat fibrosarcoma-1’ (Raf-1) protein to the
cFLIP-caspase-8 heterodimer. This complex supports
the subsequent activation of NF-Ba n d‘mitogen acti-
vated protein kinase’ (MAPK) [50], both acting as key
mediators of inflammatory or proliferative responses
and survival. Since also Bcl-10 and MALT-1 associate to
this complex [51], cFLIP could be considered as the
candidate for determining life and death by directly link-
ing CD95-costimulatory signals to TCR signaling
pathways.
So far, three cFLIP isoforms (cFLIPL,c F L I P S and
cFLIPR) were identified, with cFLIPS/R presumably med-
iating a block in apoptosis by inhibiting caspase-8 at the
DISC as mentioned above. The role of cFLIPL regarding
an inhibition at the DISC is still a matter of debate and
seems to be regulated at the level of expression
[49,51,52]. Likewise, the role of cFLIP in the activation
of NF-B might be much more complex than described
above. In fact, several groups reported inhibitory effects
of cFLIP on CD95-induced NF-B activation [53-55].
Further downstream of the CD95 apoptotic pathway,
anti-apoptotic proteins including Bcl-2/Bcl-XL and XIAP
may prevent apoptosis [7,38]. An increased expression
of anti-apoptotic checkpoint proteins in CD95-sensitive
cells could therefore shift caspase-associated death sig-
naling to NF-B-associated proliferative signaling path-
ways in the course of cellular activation [56,57].
The two faces of non-apoptotic CD95 signaling in T cells
As stated above, several earlier data pointed to a poten-
tial modulation of T cell activation by CD95 [32,33].
However, the molecular mechanism of the CD95 costi-
mulatory function had never been elucidated in detail.
Moreover, the published data about a “CD95 costimula-
tion” have been somehow inconsistent, since CD95 has
been described as a silencer or an enhancer of primary
human T cell activation [32,33,36,50,58,59].
I tw a sp r o p o s e dt h a tt h ee x p r e s s i o no fC D 9 5 Lo n
‘antigen-presenting cells’ (APC) would be responsible
for antigen-specific deletion of primed peripheral T
cells, eventually leading to T cell tolerance or immuno-
suppression [60-62]. Follow-up studies, however, pro-
vided evidence for alternate activities of APC-associated
CD95L on naïve T cells, including the complete block
of T cell activation and proliferation in the absence of
apoptosis [59,63]. Of note, it is not yet clear whether
the block in caspase-8 activation observed under such
conditions is due to an impaired recruitment to the
DISC or whether caspase-8 activation is directly abro-
gated in the CD95 complex. This suppression of T cell
activation affected several proximal TCR signaling path-
ways including the recruitment and phosphorylation of
‘ζ-chain-associated protein of 70 kDa’ (ZAP70), ‘phos-
pholipase Cg’ (PLCg), and ‘protein kinase C-Θ’ (PKC-Θ)
into lipid rafts, thereby preventing the formation of a
functional signaling platform. Furthermore, CD95-costi-
mulated T cells displayed inefficient nuclear transloca-
tion of transcription factors including the ‘nuclear factor
of activated T cells’ (NFAT), NF-Ba n dt h e‘activator
protein-1 (AP-1), reduced Ca
2+-mobilization and
decreased MAPK and caspase activation. As a conse-
quence, Strauss and colleagues reported a down-regula-
tion of activation markers and reduced secretion
of several cytokines including IL-2, IFNg or TNFa
(Figure 1). This block in cell activation through CD95 is
in line with an earlier report by Chen and co-workers,
who described an inhibition of T cell proliferation by
“CD95L-painted” K562/B7-1 cells that was only partially
caused by apoptosis induction [58]. However in both
studies, a positive costimulatory effect of CD95L had
not been noted.
It should be emphasized that this “negative costimula-
tion” is in full agreement with our own observations
employing high concentrations of immobilized CD95
agonists and thus reflects the inhibitory branch of CD95
signaling. However, our titration experiments revealed
that low doses of the very same CD95 agonists drasti-
cally augment T cell activation and proliferation under
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outcome of CD95 ligation on naïve T cells largely
depends on the “dose of agonist”, resulting in opposite
effects from a complete block of activation (at high
doses) to prominent costimulatory activation (at lower
concentrations) (Figure 2). Surprisingly, low doses of
CD95 agonists promote cell cycle progression in a much
higher portion of a given T cell population compared to
conventional costimulation through the classical costi-
mulatory molecule CD28. At the level of surface
appearance of activation markers and regarding the acti-
vation of cell cycle regulatory proteins, CD95 triggering
might in fact replace the conventional “signal 2” [39].
In our recent report, we provided a detailed analysis of
the signaling events associated with the positive costi-
mulatory activity of CD95 [39] that complemented the
inhibitory features of the CD95/CD95L-system described
by Strauss and colleagues [59]. Thus, CD95 ligation at
low agonist concentrations promotes TCR-triggered
MAPK phosphorylation, non-apoptotic caspase and NF-
B activation and the upregulation of activation markers
and anti-apoptotic checkpoint proteins [36,39,50].
Furthermore, our analyses indicate an accelerated actin-
dependent CD95 and TCR co-internalization as a
mechanism to establish receptor interference and signal-
ing crosstalk [39]. As a consequence, enhanced cell
cycle progression and proliferation are associated with
an increased cytokine production (IFNg,T N F a,I L - 2 )
[32,33,36,39,50] (Figure 3).
Given that cFLIP and the Bcl-2 family member Bcl-XL
(both upregulated in response to low concentrations of
CD95 agonists [39]) are known for their capacity to
interfere with apoptotic cell death [7,64,65], we observed
a more generalized partial apoptosis resistance upon pri-
mary TCR/CD3 activation, which was further enhanced
upon costimulation via CD95 [39]. Interestingly in this
context, it has recently been shown that the anti-apop-
totic cFLIP isoforms do not just block the initiation of
the extrinsic apoptotic pathway, but also result in
High dose of High dose of
CD95 agonists
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CTLA-4/CD95L
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Caspase-3
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Expression of activation markers  
Cell cycle progression
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Figure 1 CD95L-expressing APC down-modulate T cell
responses. High density CD95L, as expressed on transfectants or
certain activated APC or mimicked by high amounts of CD95
agonists in vitro, engages membrane CD95 and interferes with
proximal TCR signaling by inhibiting the phosphorylation of ZAP-70,
PLCg and PKC, leading to inefficient nuclear translocation of
transcription factors like NFAT, NF-B and AP-1 (Jun/c-Fos). CD95
engagement under such conditions also prevents activation of
caspases and MAPK as well as Ca
2+-mobilization. Subsequently, TCR-
induced cytokine production and upregulation of activation markers
are impaired, resulting in a CD95L-mediated complete block of cell
cycle progression in naïve T cells.
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anti-CD3
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Figure 2 Dose-dependent effects of CD95 coligation on
primary T cell activation. CD95 is capable of transducing non-
apoptotic costimulatory signals in TCR/CD3-stimulated naïve T cells.
Interestingly, the outcome of CD95 costimulation depends on the
dose of agonist. Whereas high concentrations of CD95 agonists
silence T cells, low doses augment TCR-induced activation and
proliferation. Thus CD95 can act as a silencer or enhancer of primary
T cell activation (see text for detail).
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Figure 3 Costimulation with low doses of CD95 agonists
increases primary T cell activation. CD95 coligation enhances
MAPK and NF-B activation in TCR-triggered cells and results in
accelerated induction of activation markers, cell cycle regulatory
proteins, cytokine secretion and cell cycle progression. The
incomplete cleavage of caspase-3 into p20 fragments (possibly
achieved by an interaction with XIAP) seems to be characteristic for
non-apoptotic caspase activation and becomes more prominent
upon CD95 costimulation. In line with the observed upregulation of
anti-apoptotic proteins including cFLIPR/S and Bcl-XL in the presence
of low dose CD95 agonists, CD95/TCR-stimulated cells display a
partial apoptosis resistance.
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from spontaneous apoptosis [66].
A dose-dependency of CD95 ligation had been
observed earlier for CD95-sensitive SKW6.4 cells
[65,67]. Lavrik and colleagues showed that a strong
CD95 stimulation initiated death of this EBV-trans-
formed lymphoblastoid B cell line, whereas CD95 stimu-
lation below a certain threshold level triggered cFLIP-
dependent survival associated with MAPK and NF-B
activation. In fact, these experimental observations on
life and death decisions and also on the role of cFLIP
isoforms in this context fit nicely into the computational
models that have been developed in a systems biology
approach to better understand CD95 signaling conse-
quences [65,67-69].
Based on our results in primary T cells, we proposed a
comparable threshold mechanism in primary human T
cells [39]. However, since freshly isolated T cells display
apoptosis resistance even to high concentrations of solu-
ble or immobilized CD95 agonists (in contrast to
SKW6.4 cells or activated T cells), CD95 signaling shifts
towards inhibition of cell proliferation as initially
emphasized by Strauss et al. [59] or Chen et al. [58]. As
a consequence, high concentrations block TCR signal
initiation (without inducing cell death), whereas low
concentrations result in a sustained amplification of the
TCR-induced activation processes mentioned above
(Figure 4).
Notably, differential CD95 ligation might also deter-
mine cell fate and apoptosis sensitivity outside the
immune system. Schüngel and colleagues recently
reported that depending on the efficacy of CD95 recep-
tor activation or the strength of the CD95L signal (e.g.
using monoclonal anti-CD95 antibodies or hexameric
CD95L, respectively), hepatocytes and non-parenchymal
liver cells can either behave as type I cells (following
strong CD95 receptor activation) or as type II cells
where the BH3-only protein Bid amplifies the weak
death receptor signal to render the liver cells more sen-
sitive to CD95-induced apoptosis [70].
What could be the physiological relevance of dose-
dependent CD95 signaling in T cells?
The dose-dependency of CD95 signals calls for a closer
look at the regulation of CD95L expression in cells that
come into contact with resting and/or activated CD95
expressing T cells. Still, the role of CD95L expressed on
epithelial cells of the thymus is controversially discussed.
Some studies suggested a role of CD95L and/or CD95
during positive or negative selection [71-73]. However,
most studies are again based on the gld- and lpr-models
and describe phenomenology without providing detailed
information about signaling alterations and consequences.
Although CD95L has been initially described as an
inducible, more or less T cell specific, molecule, several
studies document that also outside the thymus, CD95L
is expressed on B cells [74], on APC including macro-
phages, ‘dendritic cells’ (DC) and Langerhans cells
[75-77] and on tumour cells of different origin. With
regard to tumour cells, (high level) CD95L expression
might not only protect the tumour by inducing apopto-
sis in activated ("CD95-sensitive”) tumour infiltrating
cells, a mechanism that was referred to as ‘tumor coun-
terattack’ [78], but could also block the activation of
potentially tumour-reactive primary T cells for instance
during metastatic spreading.
Regarding B cells or APC, it has been suggested that
on those cells, CD95L might be upregulated in the
course of an immune response or during cell maturation
by yet unknown mechanisms accompanying antigen
processing and presentation [75,79,80]. Thus, APC initi-
ally express low levels of CD95L. At the onset of an
adaptive immune response to foreign antigens, the anti-
gen presentation to naive T cell may therefore be asso-
ciated with a costimulatory CD95 signal and result in
enhanced activation and proliferation, as seen in vitro
with suboptimal TCR stimulation in the presence of low
a m o u n t so fC D 9 5a g o n i s t s[ 3 9 ] .I nt h i ss i t u a t i o n ,C D 9 5
triggering would support T cell expansion and the gen-
eration of effector T lymphocytes, which at the same
time produce more ‘T helper1’ (Th1-)-type cytokines for
the activation of ‘natural killer’ (NK) cells, macrophages
and ‘cytotoxic T cells’ (CTLs). As a result of pathogen
elimination, the expansion phase is followed by a
signal 2 signal 1 APC signal 2 signal 1 APC
NaiveTcells Activated Tcells
signal 2
MHC
signal 1 APC
CD95L/FasL
signal 2
MHC
signal 1 APC
CD95L/FasL
TCR
antigen
CD95/Fas
CD95L/FasL
TCR
antigen
CD95/Fas
CD95L/FasL
H J G H
] ]
T cell
CD95/Fas H J G H
] ]
Tc e l l
CD95/Fas
T cell Tc e l l
T cell activation T cell silencing T cell survival T cell death
Figure 4 Modulation of T cell responses through CD95 in naïve
versus activated T cells. The activation state of a given T cell
(population) defines the signal threshold for pro- or non- apoptotic
CD95 signaling. At the next level, the signal strength passing
through CD95 determines whether signal transduction results in cell
death, survival, cell cycle arrest or enhanced proliferation. In naïve
CD95-resistant T cells, CD95 acts as a potent costimulatory receptor
that can transduce activatory or inhibitory signals depending on the
dose of CD95 agonists to modulate TCR/CD3 signal induction.
Activated T cells are CD95-sensitive and undergo apoptosis when
exposed to high concentrations of CD95L. In contrast, a weak CD95
stimulus (again below a certain threshold level) might induce
survival signaling in the absence of detectable cell death.
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reach their normal basal level. The reduction in T cell
numbers could be accomplished and stabilized by the
induction of apoptosis (AICD) in activated T cells on
one hand and by preventing further activation of naive
T cells on the other hand. According to the report by
Strauss and colleagues [59] and our own observations
using high doses of the CD95 agonists, this blockade
could be achieved by high levels of CD95L, potentially
on any neighboring cell. The recent reports therefore
suggest that under physiological conditions, both the
expression levels of CD95L and the threshold levels for
CD95 “signal conversion” m i g h tb em o r er e l e v a n tf o r
the regulation and fine-tuning of the immune response
than hitherto anticipated.
Along this line, it has been demonstrated that macro-
phages upregulate CD95L during an ongoing HIV-infec-
tion [81,82] and thereby contribute to the apoptotic
depletion of uninfected CD4
+ T cells [83,84]. However,
according to the report by Strauss et al. [59], another
mechanism of reducing T cell numbers during HIV infec-
tion might be the block of proliferation of resting cells. Of
course, the outcome of CD95 ligation very much depends
on the state of activation of the respective T cell popula-
tion. Infection with Cryptococcus neoformans results in an
upregulation of CD95L on ‘glucuronoxylomannan’/’toll-
like receptor-4’ (GXM/TLR-4)-triggered macrophages,
associated with increased apoptotic T cell death in acti-
vated cells. As expected, also under such conditions, cell
death induction is drastically reduced employing naïve T
cells [85]. Likewise, CD95L-expressing DC trigger apopto-
sis of pre-activated cells but induce resistance of naïve
CD4
+ and CD8
+ T cells [86]. Under pathophysiological
conditions, increased levels of CD95L might prevent initial
T cell expansion. Respective scenarios have not only been
reported for HIV [59], but also for ‘cytomegalovirus’
(CMV) [87], measles virus [88] and ‘herpes simplex virus’
(HSV) [89]. Raftery and colleagues [87] observed that
CMV-infected DC not only down-modulate MHC mole-
cules but also upregulate CD95L, thereby inducing cell
death of activated T cells and non-deletional suppression
of the surviving T cells. Thus, also an upregulation of
CD95L on infected cells may provide an effective immune
escape mechanism for certain pathogens. Recently,
Puliaeva and colleagues further suggested that the CD95/
CD95L-system also plays a role in T cell/T cell-interac-
tions. They showed in an in vivo mouse model that CD95
expression on CD4
+ T cells provides an important signal
for CD4
+ T cell expansion and is required for optimal
function of CD8
+ effector CTL [90].
Conclusion
CD95 belongs to the TNFR superfamily and is best
known for its capacity to execute cell death in CD95-
sensitive cells. In this context, CD95-induced apoptosis
plays an essential role in the maintenance of immune
homeostasis and tolerance and in immune response ter-
mination. Dysregulation of pro-apoptotic functions con-
tributes to several diseases including cancer or
autoimmune syndromes and immunodeficiencies. In
addition, non-apoptotic functions of CD95 in different
cell types regulate proliferation, differentiation or che-
motaxis. Also in T lymphocytes, CD95 acts as a dual-
function receptor that conveys its differential signals
depending on the cellular microenvironment and the
state of activation. From the most recent data, we con-
clude that low levels of CD95L on APC positively costi-
mulate naïve T cells and thus support the expansion
phase. In contrast, when CD95L is upregulated during
the immune response, this may eventually result in the
induction of apoptosis in activated cells and the preven-
tion of activation of resting cells. Under pathophysiolo-
gical conditions, the threshold levels might be shifted to
higher expression of CD95L as a mechanism of immune
evasion of certain pathogens.
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